For laboratory research use only. This page summarises published scientific literature on MOTS-C in plain English, in a neutral research style. It is not medical advice and contains no guidance on doses, administration or human use.
What is MOTS-C?
MOTS-C (Mitochondrial-derived Peptide Cell-penetrating peptide) is a recently discovered endogenous peptide composed of 16 amino acids that is encoded within the mitochondrial genome and synthesised within mitochondria. This peptide represents a groundbreaking discovery in cellular biology, establishing mitochondria as producers of signalling peptides that regulate systemic metabolic homeostasis—a paradigm shift in understanding mitochondrial biology beyond mere energy production.
MOTS-C was first identified in 2015 by researchers at the University of Southern California and subsequently characterised as a bioactive peptide with profound metabolic effects. Unlike most peptide hormones synthesised in the endoplasmic reticulum and released into circulation, MOTS-C is synthesised within mitochondria and exported to regulate metabolic signalling in target cells. This unique origin positions MOTS-C at the intersection of mitochondrial biology, metabolic homeostasis, and ageing research.
The discovery of MOTS-C catalysed identification of other mitochondrial-derived peptides (MDPs)—LEURKine, HUMRNA—establishing an entirely new class of bioactive molecules. MOTS-C remains the most extensively studied MDP and represents a novel research tool for investigating mitochondrial-systemic metabolic integration.
Mechanism of Action: AMPK Activation and Metabolic Regulation
The primary mechanism through which MOTS-C exerts its metabolic effects centres on activation of AMP-activated protein kinase (AMPK), often termed the “metabolic master switch” due to its pivotal role in cellular energy homeostasis.
Downstream AMPK Effects: Activated AMPK triggers a cascade of metabolic remodelling:
- Glucose Homeostasis: Enhanced glucose uptake into skeletal muscle and adipose tissue via GLUT4 translocation (AMPK-dependent, insulin-independent mechanism). Improved glucose utilisation and reduced hepatic glucose production. Enhanced insulin sensitivity through multiple mechanisms.
- Lipid Metabolism: Inhibition of acetyl-CoA carboxylase (ACC), reducing malonyl-CoA levels and increasing fatty acid oxidation capacity. Enhanced mitochondrial fatty acid uptake via CPT1 upregulation. Reduced de novo lipogenesis and triglyceride synthesis.
- Mitochondrial Biogenesis: Increased PGC-1α expression and activation, promoting mitochondrial biogenesis and oxidative capacity. Enhanced mitochondrial function and ATP production efficiency.
- Autophagy and Mitophagy: Enhanced autophagy pathways (ULK1 activation), promoting cellular housekeeping and proteostasis. Mitochondrial quality control through selective mitochondrial autophagy.
Molecular Integration: MOTS-C’s effects integrate multiple signalling pathways: AMPK activation, mTOR inhibition (reducing anabolic signalling), SIRT1 activation (enhancing NAD+-dependent deacetylase activity), and insulin signalling sensitisation. This coordinated metabolic remodelling underlying MOTS-C’s pleiotropic metabolic effects.
Mitochondrial Biology and Metabolic Research Applications
MOTS-C’s mitochondrial origin and metabolic effects position it uniquely within mitochondrial research. Understanding MOTS-C illuminates mitochondrial signalling beyond the classical ATP production function.
Mitochondrial-to-Nucleus Signalling: MOTS-C exemplifies retro-signalling, whereby mitochondrial stress or metabolic state communicates to the nucleus to coordinate systemic metabolic adjustments. During caloric restriction or energy stress, mitochondrial MOTS-C expression increases, triggering AMPK activation and metabolic adaptation. This mechanism enables rapid metabolic coordination in response to energy availability.
Mitochondrial Dysfunction in Metabolic Disease: In obesity and metabolic syndrome, mitochondrial MOTS-C expression is reduced. This reduction contributes to impaired glucose homeostasis and insulin resistance. Restoring MOTS-C levels (via supplementation) partially rescues metabolic function, identifying MOTS-C insufficiency as a mechanistic contributor to metabolic pathology.
Mitochondrial Proteostasis: MOTS-C-mediated autophagy and mitophagy enhancement promotes removal of dysfunctional mitochondria, maintaining mitochondrial quality and function. This proteostatic function becomes increasingly important in ageing, when mitochondrial quality control declines and accumulation of defective mitochondria contributes to age-associated metabolic decline.
Bioenergetic Resilience: MOTS-C enhances mitochondrial biogenesis and oxidative capacity, increasing cellular bioenergetic reserve. This reserve enables metabolic flexibility—the capacity to rapidly shift between fuel utilisation (glucose vs fat) in response to nutrient availability or metabolic demand.
Insulin Sensitivity and Glucose Regulation Studies
MOTS-C demonstrates robust effects on insulin signalling and glucose homeostasis, supported by comprehensive preclinical research and emerging human studies.
Exercise Performance and Endurance Research
MOTS-C demonstrates effects on exercise capacity and endurance performance, linking mitochondrial function to physical performance.
Ageing and Longevity Research: The Nuclear Translocation Hypothesis
MOTS-C demonstrates profound effects on ageing processes and may represent a novel approach to age-related metabolic decline—one of the most significant challenges in gerontology research.
Age-Related Metabolic Decline: Advancing age associates with progressive metabolic deterioration: reduced glucose tolerance, declining insulin sensitivity, decreased mitochondrial function, reduced exercise capacity, and accumulation of metabolic dysfunction. These changes contribute to age-associated diseases (type 2 diabetes, cardiovascular disease, neurodegeneration) and represent central drivers of ageing-related morbidity.
MOTS-C and Metabolic Ageing: MOTS-C levels decline with age in both animals and humans. This age-associated decline contributes to metabolic dysfunction; restoring MOTS-C levels partially reverses age-associated metabolic deterioration. This positions MOTS-C as a potentially druggable target for combating metabolic ageing.
Nuclear Translocation Under Stress: A fascinating mechanistic discovery reveals that under cellular stress (oxidative stress, energy stress), MOTS-C undergoes nuclear translocation. Within the nucleus, MOTS-C regulates gene expression through direct interactions with transcription factors or chromatin remodelling complexes. This stress-responsive nuclear translocation represents an elegant mechanism enabling rapid metabolic adaptation during acute stress—a capacity that declines with age.
Stress Response Signalling: Nuclear MOTS-C coordinates transcriptional programs promoting stress resilience: upregulation of antioxidant defence (SOD, catalase, glutathione peroxidase), DNA repair mechanisms, heat shock proteins, and metabolic adaptation. This integrated stress response enhances cellular resistance to diverse stressors (oxidative, metabolic, thermal).
Gerontological Implications: For ageing research, MOTS-C represents a pharmacological tool targeting fundamental ageing mechanisms (mitochondrial dysfunction, metabolic decline, stress vulnerability). Unlike symptomatic interventions addressing individual age-related diseases, MOTS-C addresses root causes, potentially enabling comprehensive age-related pathology prevention.
MOTS-C vs Other Metabolic Peptides: Comparative Analysis
MOTS-C operates within a growing landscape of peptide-based metabolic modulators. Understanding comparative profiles informs research selection and mechanistic insights.
MOTS-C Profile: Mitochondrial-derived, AMPK activator, comprehensive metabolic enhancer, stress resilience promoter. Enhances glucose utilisation, fatty acid oxidation, mitochondrial biogenesis, autophagy. Direct metabolic action with secondary systemic effects.
AOD-9604 Profile: Human growth hormone fragment (amino acids 176–191), lipolytic (fat-mobilising) focus, modest metabolic effects, direct adipose tissue action. Enhances fatty acid oxidation, reduces adiposity, improves glucose tolerance secondarily. More adipose-tissue-selective than MOTS-C’s systemic action.
Comparative Mechanisms: AOD-9604 mobilises adipose tissue lipid stores; MOTS-C enhances systemic metabolic capacity to utilise those fuels. MOTS-C’s AMPK activation is more comprehensive than AOD-9604’s adipose-selective mechanisms. MOTS-C demonstrates superior glucose regulation and broader metabolic improvement.
Combination Potential: The complementary mechanisms suggest potential synergy: AOD-9604 mobilising fatty acids, MOTS-C enhancing oxidative capacity to utilise those fuels. Combined use could theoretically produce superior metabolic remodelling than either alone, though systematic studies are limited.
Research Context Selection: For lipid mobilisation and localised adipose effects, AOD-9604 is optimal. For comprehensive metabolic enhancement and mitochondrial function improvement, MOTS-C is preferable. For longevity and ageing research, MOTS-C’s unique stress-response mechanisms provide advantages.
Obesity and Metabolic Syndrome: Research Context
MOTS-C demonstrates profound effects in obesity and metabolic syndrome models, positioning it as a valuable research tool for metabolic disease investigation.
Metabolic Syndrome Reversal: In established metabolic syndrome (obesity, dyslipidaemia, hypertension, insulin resistance, systemic inflammation), MOTS-C reverses multiple pathological features. Adipose tissue inflammation decreases, with reduced inflammatory cytokine production (IL-6, TNF-α, MCP-1) and enhanced anti-inflammatory signalling. Hepatic steatosis (fat accumulation) improves as de novo lipogenesis decreases and fatty acid oxidation increases.
Lipid Profile Improvement: Plasma triglycerides decrease substantially, whilst HDL cholesterol often improves. LDL particle size and composition normalise, shifting toward the more favorable larger, less-dense particle pattern. These improvements occur through both reduced hepatic VLDL production and enhanced hepatic and systemic lipid oxidation.
Inflammatory Pathway Modulation: Beyond metabolic improvements, MOTS-C reduces systemic inflammation through multiple mechanisms: AMPK-mediated NF-κB inhibition (reducing pro-inflammatory gene expression), enhanced mitochondrial quality control reducing mitochondrial-derived damage-associated molecular patterns (DAMPs), and metabolic normalisation reducing obesity-associated inflammatory signals.
Mechanistic Research Applications: For researchers studying obesity pathophysiology, metabolic syndrome development, metabolic inflammation, or mitochondrial dysfunction in metabolic disease, MOTS-C provides a tool to dissect mitochondrial contributions to metabolic disease and test mitochondrial-targeted intervention efficacy.
UK Legal Status and Regulatory Framework
Understanding MOTS-C’s UK legal status is essential for researchers and suppliers.
Current Status: MOTS-C is not licensed as a pharmaceutical product by the MHRA. It is not classified as a controlled substance. MOTS-C may be legally supplied for research and laboratory purposes, provided regulatory compliance is maintained. Supply as a cosmetic or dietary supplement is not permitted due to regulatory classifications and lack of sufficient safety data.
Regulatory Compliance: Supply of MOTS-C for research must adhere to:
- The Human Medicines Regulations 2012 (as amended) – permitting unlicensed compound supply for research
- The Medicines Act 1968 – governing investigational substance supply
- GMP standards for suppliers – ensuring product quality and purity
- REACH regulations – chemical safety compliance
Clinical Development Path: Researchers considering clinical translation of MOTS-C must navigate standard regulatory pathways: IMP Classification from MHRA, completion of preclinical toxicology and pharmacology studies, IND/CTA (Clinical Trial Application) submission, and Phase I safety studies. The early stage of MOTS-C clinical development means regulatory requirements remain stringent.
UK Sourcing and Quality Assurance
UK researchers access MOTS-C through specialised research suppliers, with quality assurance standards essential for novel peptides.
Supplier Selection Criteria: Quality suppliers provide:
- Certificates of Analysis (CoA) detailing purity, identity, and impurities
- HPLC verification of peptide purity (>95% typical)
- Mass spectrometry confirmation of molecular weight and amino acid sequence
- Endotoxin testing for parenteral preparations
- Batch-to-batch consistency documentation
- GMP certification or equivalent quality standards
Novel Compound Considerations: As MOTS-C is relatively newly discovered (first identified in 2015), supplier experience varies. Established peptide suppliers (those with extensive experience with Semax, Selank, AOD-9604, etc.) are preferable to suppliers new to MOTS-C. Verify that analytical methods (HPLC, MS) are validated specifically for MOTS-C.
Storage and Delivery: Professional suppliers maintain cold-chain integrity during shipping with temperature monitoring. Upon arrival, verify vial seal condition, powder appearance (typically white to off-white), and documentation completeness. MOTS-C’s endogenous peptide nature means it should appear similar to other peptide compounds.
Documentation: Reputable suppliers provide Material Safety Data Sheets (MSDS), technical datasheets with comprehensive characterisation data, Certificates of Analysis, and reference standards for comparison. This documentation enables regulatory compliance and publication-quality compound identification.
Limits of the evidence
Published findings come from specific study designs, often in cell systems or animals, and do not transfer automatically to other settings. A paper about a molecule is not proof that any particular batch has a given biological effect. Purity data show what is in a vial; they do not show sterility, safety or suitability for any use outside the laboratory.
Laboratory handling
- Store lyophilised powder sealed, cold (−20 °C for long-term storage), dry and protected from light.
- Let vials reach room temperature before opening to limit condensation.
- Prepare solutions with suitable laboratory solvents and calibrated equipment, and label each with lot number, concentration and date.
- Split solutions into single-use aliquots and avoid repeated freeze–thaw cycles.
- Use the peptide calculator for concentration arithmetic (mg/mL).
For laboratory research use only. MOTS-C sold by Peptides Lab UK is supplied strictly for in vitro laboratory research. It is not for human or veterinary use, and nothing on this page is medical advice or guidance on administration. UK purchasers are responsible for complying with all applicable legislation.
